Akcea Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

akceatx.com

Stage

Corporate Minority - P2P | IPO

Total Raised

$543.17M

Market Cap

1.85B

About Akcea Therapeutics

Akcea Therapeutics (NASDAQ: AKCA) is a late-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders.

Akcea Therapeutics Headquarter Location

55 Cambridge Parkway Suite 100

Cambridge, Massachusetts, 02142,

United States

760-603-2732

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Akcea Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Akcea Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Akcea Therapeutics News

Exclusive: Aspen Neuroscience collects large Series B to compete against Bayer's Parkinson's cell therapy

May 9, 2022

Specifically, should the neuroscience portion be dropped as the San Diego biotech considers expanding beyond the CNS? McDevitt, the 21-year GlaxoSmithKline veteran and former Akcea Therapeutics CEO who took over the helm of Aspen in January 2021, now has even more deep-pocketed investors to help him and his 60-plus employee team consider their voyage beyond Parkinson’s thanks to a $147.5 million Series B. Keep reading Endpoints with a free subscription Unlock this story instantly and join 141,500+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Amber Tong Senior Editor Clay Siegall, the co-founder and longtime CEO of Seagen, is on a leave of absence following an alleged incident of domestic violence, the company revealed Monday morning. While Siegall — who informed the company that he’s in the middle of a divorce — denied those allegations, the Seagen board of directors formed a committee to conduct an investigation, with the help of a law firm. In the meantime, Roger Dansey, CMO since 2018, will step in as interim CEO to lead the company as it navigates the expansion of its commercial antibody-drug conjugates while plotting the clinical advancements of experimental ones. Keep reading Endpoints with a free subscription Unlock this story instantly and join 141,500+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Jason Mast Editor SAN FRANCISCO — Seven years ago, Silicon Valley’s brashest venture capitalist invited a soft-spoken Stanford biophysicist out for pancakes not far from here, planning to make a request he publicly swore he’d never make. By that point, Marc Andreessen had already completed his rise from tech prince — Time magazine literally put him on the cover on a throne in 1996 — to tech kingmaker. The baby-faced founder of Netscape, briefly the world’s dominant web browser, re-emerged in 2009 as head of Andreessen Horowitz, or a16z for short, that quickly became one of the industry’s most sought-after VC firms. Premium subscription required Josh Sullivan Associate Editor What do you get when some of the most powerful CDMOs in the world join forces? The first SPAC dedicated to meeting the critical demand for biomanufacturing on the continent. eureKING will be a publicly listed shell company. It is backed by eureKARE, the investment company focused on developing synthetic biology and microbiome innovation across Europe. The company has plans to raise 150 million euros, Reuters reported . It will list on the Euronext Paris, and has identified 40 manufacturing targets. Michael Kloss, formerly of PHC Holdings, told Reuters that it plans to swallow three CDMOs that each make roughly 50 million euros a year over the next few years. Keep reading Endpoints with a free subscription Unlock this story instantly and join 141,500+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Beth Snyder Bulik Senior Editor As drugs in psoriasis and psoriatic arthritis therapy areas nab new indications that crisscross the two categories, dermatologists and rheumatologists are assessing their options. The twist? Emerging opinions between the two doctor groups are exactly the opposite, according to Spherix Global Insights Research analysis. Rheumatologists “heavily” prefer Interleukin 17s (IL-17s) such as Novartis’ Cosentyx and Eli Lilly’s Taltz to treat psoriatic arthritis with only 25% saying they prefer the Interleukin 23s (IL-23s) that include Janssen’s Tremfya, Sun’s Ilumya and AbbVie’s Skyrizi. Meanwhile, dermatologists much prefer IL-23s, and especially Skyrizi, by about the same margin, Spherix analysts said. Read More Kyle LaHucik Associate Editor Last month, analysts speculated the sNDA for Myovant Sciences and Pfizer’s Myfembree could be hit by a CRL after the FDA identified “deficiencies.” Now, the companies are saying the drug decision data has been pushed back. The Swiss biotech said Friday that the PDUFA date was pushed from May 6 to Aug. 6, and Cowen analysts reacted positively. “This is an encouraging development. Following the disclosure of deficiencies, we had expected a CRL today, but the extension suggests a path to approval this summer. We continue to believe MYOV is undervalued for the relugolix franchise,” Cowen analysts wrote in a note. Read More Paul Schloesser Associate Editor Belgian biotech and penny stock player Oxurion was already hovering around the $1.06/share mark this past week on the Euronext stock exchange in Brussels — and with the company’s newest announcement, its stock price has tanked. The eye-focused biotech announced a Phase II fail early Monday — in Part A of a Phase II trial on the company’s integrin antagonist candidate to treat diabetic macular edema or DME. Although the candidate, also called THR-687, was shown to be safe and well-tolerated (a fact the company emphasized), evidence to prove efficacy was “insufficient” on the main endpoints for the trial: best-corrected visual acuity (the best vision correction possible with either glasses or contact lenses) and thickness of the macula, also known as central subfield thickness. Read More May 9, 2022 08:35 AM EDT Zachary Brennan Senior Editor The FDA’s top vaccine leader told a congressional committee on Friday afternoon that although the adult vaccines had to meet a 50% threshold for efficacy against Covid-19 infections, that same standard will not need to be met for the vaccines for the youngest group of children, for which a vaccine is not yet available. The agency is currently reviewing data from Moderna’s two-shot vaccine for this youngest group as it awaits further data from Pfizer on its potential three-dose shot. The agency previously scheduled and then canceled an adcomm to review data on two doses of Pfizer’s vaccine for children under the age of 5. Read More

Akcea Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Akcea Therapeutics Rank

  • Where is Akcea Therapeutics's headquarters?

    Akcea Therapeutics's headquarters is located at 55 Cambridge Parkway, Cambridge.

  • What is Akcea Therapeutics's latest funding round?

    Akcea Therapeutics's latest funding round is Corporate Minority - P2P.

  • How much did Akcea Therapeutics raise?

    Akcea Therapeutics raised a total of $543.17M.

  • Who are the investors of Akcea Therapeutics?

    Investors of Akcea Therapeutics include Ionis Pharmaceuticals.

  • Who are Akcea Therapeutics's competitors?

    Competitors of Akcea Therapeutics include Ionis Pharmaceuticals.

You May Also Like

Dicerna Pharmaceuticals Logo
Dicerna Pharmaceuticals

Dicerna Pharmaceuticals is a pharmaceutical company developing RNA interference (RNAi)-based therapeutics against genetically-defined targets in multiple disease areas, including cancer. Dicerna's therapeutic approach utilizes its Dicer Substrate siRNA (DsiRNA) molecules and EnCore drug delivery technologies to silence previously undruggable disease targets, offering a potential new treatment option for patients. Dicerna delivers its DsiRNA molecules to cancer cells using its EnCore lipid nanoparticle drug delivery technology. EnCore has been specifically engineered to accumulate in tumors and mediate efficient delivery of the DsiRNAs to the RNAi machinery in the cancer cell cytoplasm. Encore particles are well tolerated and manufactured using well-established unit operations to ensure commercial scalability.

Regulus Therapeutics Logo
Regulus Therapeutics

Regulus Therapeutics (NASDAQ: RGLS), a biopharmaceutical company, focuses on the discovery and development of drugs that target RNAs to treat a range of diseases in the United States. The Company uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. Its clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 to treat nonalcoholic steatohepatitis in patients with type 2 diabetes/pre-diabetes. The company has strategic alliance with GSK to discover and develop microRNA therapeutics for immuno-inflammatory diseases; Sanofi to discover and develop microRNA therapeutics for fibrotic diseases; AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases, and oncology; and Biogen to evaluate the use of microRNA signatures as a biomarker for human patients with various sclerosis.

Sarepta Therapeutics Logo
Sarepta Therapeutics

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates.

Silence Therapeutics Logo
Silence Therapeutics

Silence Therapeutics (LON: SLN) focuses on the development of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins.

Alnylam Pharmaceuticals Logo
Alnylam Pharmaceuticals

Alnylam Pharmaceuticals (NASDAQ: ALNY) is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company believes that are many new therapeutic frontiers for its RNA technology, including applications in vaccine development, stem cell biology, bio-processing, genomics and biologics.

WAVE Life Sciences Logo
WAVE Life Sciences

WAVE Life Sciences is utilizing its synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. Given the versatility of its chemistry platform, WAVE's pipeline is designed to span multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.